B-4T2001 is under clinical development by Bio4t2 and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how B-4T2001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
B4T2-001 is under development for the treatment of metastatic solid tumors including gastric or gastroesophageal junction adenocarcinoma, pancreatic cancer, non-small cell lung cancer, breast cancer and colorectal cancer. The therapeutic candidate comprises T cells genetically modified to express chimeric antigen receptors (CAR) targeting tumor associated antigens. It is being developed based on PrismCore, an artificial intelligence (AI) platform. It is administered through parenteral route.
Bio4t2 is a preclinical biopharmaceutical company developing single-target and combo-therapeutic CAR-T therapies targeting solid tumors. Bio4t2 is headquartered in San Diego, California, the US.
For a complete picture of B-4T2001’s drug-specific PTSR and LoA scores, buy the report here.